Efficacy of octreotide in treating advanced gastrointestinal and pancreatic neuroendocrine tumours: A retrospective cohort study

#4440

Introduction: Treatment of advanced gastroenteropancreatic neuroendocrine tumours (GEP-NETs) lacks high-level evidence and remains controversial.

Aim(s): The objective of this study was to determine whether octreotide is a potential treatment option for patients with advanced GEP-NETs through real-world studies.

Materials and methods: Patients with advanced GEP-NETs at our hospital between January 1, 2007, and May 14, 2024, identified; 51 patients received octreotide therapy. Progression-free survival (PFS) and overall survival (OS) were calculated for these patients and stratified by the primary tumour site.

Conference:

Presenting Author: Wang H

Authors: Wang H, Wang Y, Wang C, Wang G, Chi Y,

Keywords: adjuvant therapy, octreotide, gastroenteropancreatic neuroendocrine tumour,